empagliflozin
Boehringer Ingelheim,eli lilly
[]
#esccongress 2022
proteomic analysis to investigate the mechanism of #sglt2i benefit in #hf patients. data from #emperor trials patients shows a hit on #autophagy being promoted by #sglt2i
Head of cardiology, ICCU & cathlab, FESC @chru_tours @T2i_research #Medicalpedagogy @FacmedTours @UnivTours @SFCardio ???????? @uoftalumni @fedecardio